Lyme disease can trigger abnormalities across a surprisingly wide range of routine and specialized lab tests, from white blood cell counts and liver enzymes to inflammatory markers and cardiac enzymes. No single blood test reliably confirms the diagnosis on its own, which is part of what makes Lyme disease frustrating for patients and clinicians alike. The standard antibody tests miss a large share of early infections, and other lab findings tend to be subtle and nonspecific. Understanding which labs change and when they change gives you a much better picture of what your results actually mean.
Complete Blood Count Changes
A standard complete blood count, or CBC, often looks unremarkable at first glance in someone with early Lyme disease. The total white blood cell count usually stays within the normal range. But when you look at the individual cell types, patterns emerge. A study comparing over 230 antibiotic-naive patients with early Lyme disease to controls found that patients had significantly lower lymphocyte counts, higher monocyte counts, and a higher ratio of neutrophils to lymphocytes compared to healthy individuals. Those same markers shifted significantly when researchers compared patients’ own pre-infection blood work to their acute-phase values.1PubMed Central. A sex-based analysis of complete blood count features during acute, untreated Lyme disease
Roughly a quarter of early Lyme patients had abnormally low lymphocyte counts, and this was more common in men than women (about 32% vs. 20%).1PubMed Central. A sex-based analysis of complete blood count features during acute, untreated Lyme disease These shifts are not dramatic enough to raise alarms on their own, but they can support the clinical picture when a doctor is already considering Lyme. A mildly depressed lymphocyte count with a modestly elevated neutrophil-to-lymphocyte ratio, in someone who has been in tick habitat, is a clue worth noticing rather than dismissing.
Liver Enzyme Elevations
Liver tests are abnormal more often than most people expect in early Lyme disease. In one study of patients with the classic erythema migrans rash, 40% had at least one abnormal liver test, and about a quarter had more than one.2PubMed. Liver function in early Lyme disease The most commonly elevated markers were GGT and ALT, each abnormal in roughly a quarter of patients. Patients with early disseminated disease (where the infection has spread beyond the initial tick bite site) were twice as likely to have elevated liver enzymes compared to those with purely localized disease.
The good news is that these elevations tend to be mild and usually do not cause noticeable symptoms. Most resolved or improved within three weeks of starting antibiotic therapy.2PubMed. Liver function in early Lyme disease Still, this finding catches people off guard. If you show up at a clinic with flu-like symptoms and mildly elevated liver enzymes, the differential diagnosis could head in the wrong direction toward hepatitis or medication side effects unless Lyme is on the radar.
Inflammatory Markers
C-reactive protein (CRP) and a related marker called serum amyloid A (SAA) both rise in early Lyme disease. CRP and SAA levels were significantly elevated in both early localized and early disseminated infections compared to healthy controls.3PubMed Central. Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease The timing matters: by the later stages of active Lyme infection, SAA levels returned to normal, while CRP stayed elevated only in certain chronic presentations like antibiotic-refractory Lyme arthritis and post-treatment Lyme disease syndrome.
An elevated CRP in someone with Lyme disease is not diagnostically specific (CRP rises with dozens of different infections and inflammatory conditions), but the pattern of which inflammatory markers stay elevated and which normalize can help clinicians track disease progression. If CRP remains stubbornly high after treatment, it may signal ongoing inflammation even when other tests have normalized.
Why Standard Antibody Tests Miss Early Infections
The conventional approach to confirming Lyme disease in the lab is a two-tiered antibody test: an initial screening assay followed by a Western blot to confirm. This protocol works well for late-stage disease but performs poorly in the early weeks of infection, when most people first seek medical attention.4PubMed Central. Evaluation of Modified 2-Tiered Serodignostic Testing Algorithms for Early Lyme Disease The immune system simply has not had enough time to produce detectable levels of antibodies against the Lyme bacterium.
How insensitive are these tests early on? A study evaluating multiple testing algorithms in well-characterized early Lyme cases found that the standard two-tiered approach detected as few as 22-29% of confirmed infections, depending on which specific test kit was used.5PubMed Central. Evaluation of standard and modified two-tiered testing algorithms using well-characterized early Lyme disease samples That means the majority of people with genuine early Lyme disease receive a negative serologic result. This is the single most important lab caveat to understand: a negative Lyme antibody test in the first few weeks of symptoms does not rule out Lyme disease. Doctors in endemic areas know this and are trained to diagnose early Lyme clinically based on the rash and exposure history, regardless of what the antibody test says.
There is also a small but real population of patients who remain seronegative even with chronic, clinically active Lyme disease. Research has documented patients with ongoing symptoms who never developed diagnostic antibody levels, despite having measurable cellular immune responses to the Lyme bacterium.6PubMed. Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi These cases are uncommon but important because they remind us that antibody-based testing has inherent blind spots.
Modified Two-Tiered Testing
Because the standard approach misses so many early infections, researchers have developed modified two-tiered testing (MTTT) algorithms that replace the Western blot with a second, different antibody screening assay. A study using a two-EIA approach (two different enzyme immunoassays back to back) found that the modified algorithm caught about 61% of early Lyme cases compared to 48% for the standard method, while maintaining the same high specificity of roughly 99.5%.7PubMed. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay
In a real-world clinical evaluation, the MTTT detected about 28% more cases of early Lyme infection than the traditional protocol, with an estimated specificity of 99.6%.8PubMed Central. Modified Two-Tiered Testing Enzyme Immunoassay Algorithm for Serologic Diagnosis of Lyme Disease The CDC now endorses MTTT as an acceptable alternative, and many reference labs have adopted it. This is a meaningful improvement, though it still misses a substantial share of early cases. The sensitivity gap narrows considerably in later-stage disease, where both the standard and modified approaches reach essentially 100% sensitivity.7PubMed. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay
Cerebrospinal Fluid in Lyme Neuroborreliosis
When Lyme disease affects the nervous system, spinal fluid analysis becomes the key diagnostic tool. In acute Lyme neuroborreliosis, every patient in one retrospective study had elevated white blood cell counts in their cerebrospinal fluid, predominantly lymphocytes. Intrathecal production of antibodies (meaning antibodies made within the central nervous system itself rather than just leaking in from the blood) was found in the majority: IgM antibodies were produced within the central nervous system in about 70% of cases, and IgG in about 20%. Elevated Borrelia-specific antibody indices in the spinal fluid were present in over 80% of confirmed cases.9PubMed Central. Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis
A newer marker that has gained attention for neuroborreliosis is CXCL13, a chemokine that recruits immune cells to the central nervous system. A meta-analysis found that CXCL13 in spinal fluid had a pooled sensitivity of about 89% and specificity of about 96% for diagnosing Lyme neuroborreliosis.10PubMed. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis: A systematic review and meta-analysis One smaller study reported even higher sensitivity, with a normal CXCL13 level essentially ruling out the diagnosis.11PubMed. CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine CXCL13 is particularly useful because it can detect neuroborreliosis even in patients who do not yet have elevated white cell counts in their spinal fluid, catching cases that the traditional criteria would miss.
Synovial Fluid in Lyme Arthritis
When Lyme disease causes joint inflammation, especially in the knee, joint fluid analysis typically shows a high white blood cell count dominated by neutrophils. In children, the median synovial fluid white cell count in Lyme arthritis was about 54,000 cells per microliter, with over half of patients exceeding 50,000.12PubMed Central. Hip Synovial Fluid Cell Counts in Children From a Lyme Disease Endemic Area Those numbers overlap with what you see in bacterial joint infections (septic arthritis), which creates a diagnostic challenge. Septic arthritis tends to produce even higher counts (a median above 126,000 in the same study), but the overlap zone is wide enough that you cannot distinguish the two by cell count alone.
PCR testing of synovial fluid offers a way to confirm the diagnosis. The Lyme bacterium’s DNA can be detected in joint fluid with sensitivity above 90% when multiple genetic targets are used, making it one of the few body fluids where direct molecular detection of Lyme is reliably useful.13PubMed Central. Diagnosis of lyme borreliosis In contrast, PCR on blood or spinal fluid has much lower sensitivity for Lyme disease. Skin biopsies from the erythema migrans rash also yield high sensitivity with PCR and culture, though those are rarely needed since the rash is usually recognizable on sight.
Cardiac Markers in Lyme Carditis
Lyme carditis is uncommon but potentially serious, and it produces its own set of lab abnormalities. The hallmark is some degree of heart block on an electrocardiogram, but standard cardiac biomarkers can also be strikingly abnormal. Case reports describe patients with significantly elevated troponin levels, the enzyme released when heart muscle is damaged, along with elevated CRP.14CHEST. Lyme Carditis Buried Beneath ST-Segment Elevations The EKG findings can mimic a heart attack, with ST-segment elevations in specific leads, leading some patients straight to the cardiac catheterization lab before anyone considers an infectious cause.15PubMed Central. The Great Imitator: A Case of Lyme Carditis Mimicking ST Elevation Myocardial Infarction
Lyme carditis is a case where the lab abnormalities actively mislead if the clinical context is ignored. A young person in a Lyme-endemic area presenting with new-onset heart block and elevated troponin deserves Lyme testing before being treated for a heart attack. The cardiac findings resolve with appropriate antibiotic therapy in most cases, which is a very different outcome from true coronary artery disease.
When Co-infections Scramble the Picture
Ticks that carry Lyme disease often carry other pathogens at the same time, and co-infections can dramatically alter the lab profile. Babesiosis, caused by a malaria-like parasite, produces hemolytic anemia (low hemoglobin from red blood cell destruction), elevated lactate dehydrogenase, low platelet counts, and parasites visible on a blood smear. Anaplasmosis typically causes low white blood cell counts, low platelet counts, and elevated liver enzymes. A case report of triple co-infection (Lyme plus babesiosis plus anaplasmosis) documented hemoglobin of 6.9 g/dL, platelet count of 124,000, and LDH of 709 U/L, with 13% parasitemia on peripheral smear.16PubMed Central. Severe Babesiosis With Lyme Disease and Anaplasma Phagocytophilum Coinfection in a Dialysis-Dependent Patient Without Rash or Organomegaly
The practical takeaway is that any lab picture that seems “too abnormal” for Lyme alone should prompt consideration of co-infections. Lyme by itself does not cause significant anemia or dramatically low platelet counts. If you see those findings alongside positive Lyme antibodies, babesiosis or anaplasmosis testing is warranted. Co-infections are not rare in endemic areas, and missing one can mean inadequate treatment since each pathogen requires a different antibiotic regimen.
After Treatment: What Labs Show and Do Not Show
One of the more frustrating aspects of Lyme disease is what happens with lab values after treatment. Antibodies against the Lyme bacterium can remain positive for months or even years after successful antibiotic therapy. A positive antibody test after treatment does not mean you still have an active infection. It means your immune system remembers the encounter. There is no reliable lab marker that distinguishes between a past, treated infection and an ongoing one.
For patients who develop persistent symptoms after treatment (sometimes called post-treatment Lyme disease syndrome, or PTLDS), the lab picture is even less helpful. As of now, PTLDS is diagnosed clinically because no laboratory or tissue test can reliably confirm it.17PubMed Central. What Makes It Tick: Exploring the Mechanisms of Post-treatment Lyme Disease Syndrome CRP may remain elevated in some patients with post-treatment symptoms, as noted earlier,3PubMed Central. Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease but that finding is neither sensitive nor specific enough to serve as a diagnostic tool for PTLDS.
Autoantibodies and Rheumatologic Mimicry
Lyme disease has been called “the great imitator” partly because it can trigger immune responses that look like autoimmune conditions on standard lab panels. Some patients with Lyme develop positive antinuclear antibody (ANA) tests, a finding typically associated with lupus and other autoimmune disorders. One explanation is that prolonged infection with the Lyme bacterium can provoke autoimmune-like changes in a small fraction of patients.18New Medicine. Antinuclear antibodies in patients with Lyme disease This means a positive ANA in a patient from a Lyme-endemic region who also has joint pain does not automatically point toward lupus; it could be Lyme stirring up the immune system in unfamiliar ways.
Rheumatoid factor and other nonspecific immunologic markers can also be mildly positive in Lyme patients. These findings occasionally lead to misdiagnosis, especially when the tick bite was unnoticed and no rash appeared. If you receive a new autoimmune-sounding diagnosis and live in or have visited a region with Lyme-carrying ticks, it is worth making sure Lyme was adequately considered and tested for.
Emerging Lab Approaches
Because conventional testing fails so many early-stage patients, several newer approaches are in various stages of development. Gene expression profiling, which measures how human immune genes respond to infection rather than looking for antibodies against the pathogen, has shown promise. Researchers identified a sustained pattern of gene activity that differs between Lyme patients and healthy controls, and this pattern is detectable even during the early “window period” before antibodies become measurable.19PubMed Central. Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease A gene expression classifier built from these signatures showed potential clinical utility, including the ability to identify early Lyme patients who tested negative on conventional serology.20PubMed Central. A diagnostic classifier for gene expression-based identification of early Lyme disease
Machine learning analyses of gene expression datasets have also pointed to specific immune-related genes as potential diagnostic biomarkers.21PubMed Central. Identification of potential biomarkers for Lyme disease using bioinformatics and machine learning T-cell-based assays like ELISPOT, which measure the cellular arm of the immune response rather than circulating antibodies, are another area of active investigation and could theoretically catch infections before seroconversion.22PubMed Central. ELISPOT assays and their diagnostic potential in Lyme disease and Lyme neuroborreliosis None of these tools have reached routine clinical use yet, but they represent a genuine shift in strategy: instead of waiting for the pathogen to provoke a measurable antibody response, the new approach listens to how the host’s own biology reacts to the infection.
The Practical Limits of Any Single Lab Test
If there is one recurring theme across all of these lab categories, it is that Lyme disease resists diagnosis by any single test at any single time point. The CBC changes are subtle and nonspecific. Liver enzymes are elevated in many other conditions. CRP tells you something is inflamed without saying what. Antibody tests miss most early cases. Even the spinal fluid and synovial fluid analyses, which perform much better, are only relevant when specific organ systems are involved. The timing of the test relative to the onset of infection matters enormously: a test drawn in the first week will look different from one drawn at six weeks, which will look different again at six months.
Doctors in Lyme-endemic areas learn to read the full mosaic: a constellation of mild CBC shifts, mildly elevated liver enzymes, an elevated CRP, a compatible exposure history, and the right clinical picture collectively carry more diagnostic weight than any one abnormal lab value. If you are trying to interpret your own labs after a tick bite, the most important thing to know is that normal results in the first few weeks do not mean you are in the clear, and mildly abnormal results across several categories can be the loudest signal the disease gives before antibodies finally catch up.